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Isolated extramedullary disease (EMD) is uncommon, especially in acute promyelocytic leukemia (APL) after
allogeneic hematopoietic stem cell transplantation (HSCT). We review the literature and present a 32 year old
woman with APL who developed multiple EMDs after allogeneic HSCT within the calvarium, and later found to
have various isolated lesions including femur, humerus and thoraco lumbar vertebrae. She was treated with local
radiotherapy (XRT) to EMD lesions, all-trans retinoic acid, arsenic trioxide and donor lymphocyte infusion at different
time points in her clinical course, without success. Out of reported cases in clinical setting as ours, average onset of
isolated EMD is 25 months and median survival 14 months. Effective treatment of isolated EMD after HSCT is not
yet clear, but ATO in combination with local XRT, tamibarotene and second HSCT have shown good results in
some reported cases, but accumulation of more cases is needed to elucidate optimal therapy in such setting.Introduction
Among the more treatable subtypes of acute myeloid
leukemia (AML) is acute promyelocytic leukemia (APL).
Nearly all patients with APL have a translocation of
chromosomes 15 and 17, resulting in the fusion between
RARα (retinoic acid receptor α), which encodes a retin-
oic acid receptor, and the promyelocytic leukemia (PML)
protein (Licht 2009). “Myeloid sarcoma”, a solid extra-
medullary mass composed of immature myeloid cells,
was first described by Burns in 1811 (Burns 1823). King
(1853) used the term “chloroma” because of its greenish
appearance, caused by myeloperoxidase in the leukemic
cells (King 1853). Although myeloid sarcomas usually
appear as a manifestation of systemic leukemias, they
occasionally precedea marrow relapse and may be the
presenting finding (Mwanda and Rajab 1999). We
present a case of multiple skull lesions of myeloid sar-
coma in a patient with APL that occurred seven months* Correspondence: s0koth02@cardmail.louisville.edu
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(HSCT). For the rest of this review, myeloid sarcomas
will be referred to as extramedullary disease (EMD).Case report
The patient, a 32 year-old woman, was diagnosed with
APL (bcr1 subtype) and treated at an area hospital with
standard oral all-trans retinoic acid (ATRA), cytarabine
and idarubicin induction with initial complete remission
(CR). She maintained CR status for 18 months with 2
courses of consolidation therapy consisting of idarubicin
and cytarabine. However, she relapsed in BM and CNS
while being on ATRA as maintenance therapy. She had a
successful re-induction with arsenic trioxide (ATO) and
intrathecal cytarabine followed by high-dose busulfan and
etoposide with autologous PML/RARα PCR-negative
hematopoietic cells rescue. She relapsed in 7 months and
was referred to our institution for an allogeneic HSCT
from her HLA matched sister after cyclophosphamide and
total body irradiation (TBI) conditioning regimen. She
achieved full donor chimerism with no molecular evidence
of disease. Seven months later, she presented with rightan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the right frontal area.
Magnetic resonance imaging (MRI) showed multiple
enhancing lesions within the calvarium, with most
prominent lesion in right frontal bone, measuring 2.0 ×
0.9 cm that were not present on MRI done before allo-
geneic HSCT (Figure 1). The lesions were iso- to slightly
hypointense on T1 and isointense on T2-weighted
images. Subsequent skeletal survey and whole body
PET/CT imaging showed multiple bony lesions involving
frontal and parietal bones, bilateral glenoid fossae, prox-
imal left femur, distal left humerus and T5, T9 and L4
vertebral bodies.
Biopsy of right frontal lesion revealed EMD that
expressed CD45 (dim to moderate), CD34 and CD117
(focal weak); and did not express CD56 and CD68. Fluor-
escent in-situ hybridization (FISH) identified 22 out of 50
cells positive for PML/RARα translocation. It was clear
that these EMD lesions were secondary to her APL. Iliac
crest bone marrow biopsy showed no morphologic
evidence of leukemia and chimerism evaluation byFigure 1 a- Normal pre-allogeneic HSCT MRI of brain. b and c- Post co
enhancing lesions measuring up to 1.6 × 0.8 cm in the left frontal, 2.0 × 0.9
within the calvarium. d- X-ray of skull, frontal view showing lytic lesions inmicrosatellite polymorphisms showed 100% of cells of
donor origin; peripheral blood PCR for PML/RARA tran-
script was negative.
Post-transplant immunosuppression was discontinued;
she was treated with ATRA, intrathecal methotrexate, and
radiation therapy (XRT) to skull and proximal left femur.
After radiation therapy (a total of 20 Gy in 10 fractions),
she received two months of ATO, but had progressive dis-
ease evident on whole body PET/CT imaging. She was
then treated with high-dose cytarabine and idarubicin with
infusion of stored donor hematopoietic cells (DLI), but
died of complications 16 days after starting therapy. CT
scan of head without contrast done day the before her
death re-demonstrated the skull lesions.
Figure 2 includes a summary of clinical course of our
patient.
Discussion
In this report, we present a patient with CD56 negative
APL after allogeneic HSCT who developed multiple
EMD without BM relapse (isolated EMD) early in herntrast 3D spoiled gradient echo showing numerous thickened contrast
cm in the right frontal and 2.7 × 0.5 cm in the left parietal region,
the frontal and parietal bones.
Figure 2 Timeline of course of disease and treatment. - PML/RARα transcript. *- in bone marrow by PCR, **- in peripheral blood. Diag- Diagnosed,
APL- Acute promyelocytic leukemia, HSCT- Hematopoietic stem cell transplantation, dz- disease, CNS- Central nervous system, ATRA- All-trans retinoic
acid, ATO- Arsenic trioxide, MMF- Mycophenolate mofetil, IT- Intra-thecal, CT- Consolidation therapy.
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to EMD lesions, ATRA, ATO and DLI at different points
of time, without success.
In general, isolated EMD of acute myeloid leukemia
(AML), following allogeneic HSCT is uncommon, and
occurs in about 0.65% of all HSCT cases as estimated from
the European BM Transplant Registry, with higher rates
of up to 10% reported in long-term survivors (Bekassy
et al. 1996). In contrast to our patient, who remained in
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There have been 12 reported cases, including ours, of
isolated EMD with APL after HSCT (Table 1). Among
them, reported sites of EMD are skin, testes, bone, CNS,
spine, psoas muscle, middle ear, scalp, breast, nasal cav-
ity, pharynx and bowel. There is no obvious conclusion
to site predilection.
Average onset of EMD after HSCT in APL patients is
19 months, ranging from 7 months to 54 months. OurEMD after HSCT
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the earliest of reported cases with EMD. Significance of
such wide range of onset remains unknown.
There are no known risk factors for EMD (Kai et al.
2006), but several have been postulated. Some authors
have suggested an increase in the incidence of EMD
since the introduction of ATRA in the treatment of
APL. Modulation of APL blasts and endothelial cells ad-
hesion molecules, and upregulation of the granulocyte-
colony stimulating factor receptor are some of the pro-
posed mechanisms (de Botton et al. 2006; Weiss and
Warrell 1994; Wiernik et al. 1996). The expression of
CD56 has been associated with an increase in EMD and
resistance to ATRA and anthracycline therapy (Montesi-
nos et al. 2011). The role of ATRA in the development
of EMD in APL remains controversial, especially in
CD56 negative EMD, as in our case (Ito et al. 2004).
Given the universal use of ATRA in APL and the rarity
of EMDs, ATRA seems to have only a small role, if any,
in development of EMDs. Kai et al. speculated that non-
TBI containing regimens might increase the risk for
EMD after HSCT in APL (Kai et al. 2006). Since only
three of the reported cases received TBI-containing regi-
men, more cases need to be analyzed to elucidate the
role of conditioning regimen as a risk factor for EMD. It
has also been suggested that certain ethnic groups may
be at higher risk of EMD in APL (Wiernik et al. 1996).
Some investigators suggested that tissue injury caused
by diagnostic procedures and bleeding leads to occur-
rence of EMD via leakage of leukemic cells, growth fac-
tors, and cell mediators (Sanz et al. 2000). Except for
ATRA, our patient did not have any of these proposed
risk factors.
Biopsy is the most preferred diagnostic method for
EMD. Our biopsy result differs from the observation of
Pileri et al. and Campidelli et al. (Campidelli et al. 2009;
Pileri et al. 2007), in that, EMD, in our case, did not ex-
press CD68/KP1. The vast majority of normal CD34
positive hematopoietic precursors are CD68 negative,
whereas AML CD34 positive blasts are usually CD68
positive. CD68 epitopes have been suggested as a potential
target for leukemia-reactive cytotoxic-T cell (Sadovnikova
et al. 2002). But, patients such as ours may not benefit
from such therapy.
Bony EMD lesions appear lytic rather than sclerotic
(Libson et al. 1986; Cho et al. 1990). On MRI, they are
typically iso- to slightly hypointense on T1- and isoin-
tense on T2-weighted images relative to brain tissue
(Kao et al. 1987). Both CT scan and MRI are diagnostic-
ally very useful, but MRI better reveals the exact extent
of the tumor and the potential invasion of the cranial
nerve or a intracranial structure (Chang et al. 2009).
As evident from Table 1, BM status after EMD has lit-
tle influence on patient survival. Our patient remainedin CR and showed 100% donor chimerism even though
she succumbed to her progressive disease within 8 months.
During the course of APL, recognition of EMD is im-
portant as aggressive induction chemotherapy or XRT
can induce CR. Several treatment options for isolated
EMD after allogeneic HSCT in APL patients have been
postulated, which include local XRT, ATRA, tamibaro-
tene (earlier known as Am80), ATO, DLI, or a second
allogeneic HSCT (Kai et al. 2006). Successful treatment
was documented with gemtuzumab ozogamicin (Mylo-
targ) by many authors before FDA withdrew it in 2010
(Cohen et al. 2002; Ando et al. 2010). Treatment tried in
the reported cases of post-HSCT EMDs in APL patients
are summarized in Table 1. The combination therapy of
ATO and XRT for APL EMDs may be reasonable, since
enhancement of sensitivity to XRT by ATO treatment
has been reported for some kind of solid tumors (Griffin
et al. 2005), though, as evident from Table 1, treatment
with ATO and local XRT has not been fully explored in
such setting. The longest survivor had a second allogen-
eic HSCT, suggesting that this approach may be the only
curative one.
Although long-term survival has occasionally been
achieved, the prognosis for EMD patients is generally
poor, particularly when they occur during remissions
and after HSCT (Bekassy et al. 1996). Median survival
after EMD in such setting is 14 months (range: 1–43
months).Conclusion
EMD is uncommon, especially in APL after treatment.
Average onset of isolated EMD after HSCT in APL
patients is 25 months. The role of ATRA in development
of EMDs needs to be elucidated, especially in CD56
negative cases. Despite graft versus host disease and the
potential graft versus leukemia effect, our patient had
EMD and maintained 100% donor chimerism. In setting
as our patient’s, BM status after EMD has little influ-
ence, if at all, in overall patient survival. There is a po-
tential for research in novel therapies targeting surface
markers, especially in CD68 negative myeloid cells.
Treatment of isolated EMD after HSCT remains a chal-
lenge. ATO and local XRT have shown good response in
some reports but a second allogeneic HSCT may be
needed for long-term survival.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SK carried out the patient chart review, reviewed the current literature and
drafted the manuscript. GH and RH provided with scientific conclusions after
analysis of the case report and reviewed literature, and edited the
manuscript. SS reviewed and analyzed the biopsy, immunostaining and PCR
results for our case. All authors read and approved the final manuscript.
Kothari et al. SpringerPlus 2013, 2:49 Page 5 of 5
http://www.springerplus.com/content/2/1/49Author details
1Division of Blood and Bone Marrow Transplant, University of Louisville,
James Graham Brown Cancer Center, 529 South Jackson Street, Louisville, KY
40202, USA. 2Department of Pathology and Laboratory Medicine, University
of Louisville, Louisville, KY 40292, USA.
Received: 18 October 2012 Accepted: 9 February 2013
Published: 12 February 2013References
Ammatuna E, Borza PA, Iori AP, Petti MC, Pescarmona E, Diverio D, Lo-Coco F
(2005) Multiple relapses and extramedullary localization with scalp and breast
involvement in a case of acute promyelocytic leukaemia. Leukemia 19
(3):479–480. doi:10.1038/sj.leu.2403632
Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y (2010)
Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse
after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med
220(2):121–126
Bekassy AN, Hermans J, Gorin NC, Gratwohl A (1996) Granulocytic sarcoma after
allogeneic bone marrow transplantation: a retrospective european
multicenter survey. Acute and chronic leukemia working parties of the
European group for blood and marrow transplantation. Bone Marrow
Transplant 17(5):801–808
Burns A (1823) Observations on the surgical anatomy of the head and neck. In:
Pettison GS (ed) 4 edn. Baltimore, USA
Campidelli C, Agostinelli C, Stitson R, Pileri SA (2009) Myeloid sarcoma:
extramedullary manifestation of myeloid disorders. Am J Clin Pathol 132
(3):426–437. doi:10.1309/AJCP1ZA7HYZKAZHS
Chang KH, Kim DK, Jun BC, Park YS (2009) Temporal bone myeloid sarcoma. Clin
Exp Otorhinolaryngol 2(4):198–202. doi:10.3342/ceo.2009.2.4.198
Cho JS, Kim EE, Ro JH, Pinkel DP, Goepfert H (1990) Mandibular chloroma
demonstrated by magnetic resonance imaging. Head Neck 12(6):507–511
Classen CF, Debatin KM, Friedrich W, Schulz AS (2003) Long-term remission of
APL with a second allogeneic BMT after CNS relapse following HLA-identical
allogeneic BMT. Bone Marrow Transplant 32(8):843–846. doi:10.1038/sj.
bmt.1704225
Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta
S, Gewirtz AM, Stadtmauer EA (2002) Gemtuzumab ozogamicin (Mylotarg)
monotherapy for relapsed AML after hematopoietic stem cell transplant:
efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow
Transplant 30(1):23–28. doi:10.1038/sj.bmt.1703602
de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD,
Recher C, Ades L, Quesnel B, Brault P, Fey M, Wandt H, Machover D, Guerci
A, Maloisel F, Stoppa AM, Rayon C, Ribera JM, Chomienne C, Degos L,
Fenaux P (2006) Extramedullary relapse in acute promyelocytic leukemia
treated with all-trans retinoic acid and chemotherapy. Leukemia 20(1):35–41.
doi:10.1038/sj.leu.2404006
Forrest DL, Dalal BI, Naiman SC, Horsman DE, Berry BR, Parslow MI, Singh CP,
Benny WB, Barnett MJ (1997) Testicular relapse of acute promyelocytic
leukemia after allogeneic BMT. Bone Marrow Transplant 20(8):689–690.
doi:10.1038/sj.bmt.1700948
Griffin RJ, Williams BW, Park HJ, Song CW (2005) Preferential action of arsenic
trioxide in solid-tumor microenvironment enhances radiation therapy. Int J
Radiat Oncol Biol Phys 61(5):1516–1522. doi:10.1016/j.ijrobp.2004.12.058
Ito S, Ishida Y, Oyake T, Satoh M, Aoki Y, Kowata S, Uchiyama T, Enomoto S,
Sugawara T, Numaoka H, Suzuki K, Murai K (2004) Clinical and biological
significance of CD56 antigen expression in acute promyelocytic leukemia.
Leuk Lymphoma 45(9):1783–1789. doi:10.1080/10428190410001683624
Kai T, Kimura H, Shiga Y, Ogawa K, Sato H, Maruyama Y (2006) Recurrent
extramedullary relapse of acute promyelocytic leukemia after allogeneic stem
cell transplantation: successful treatment by arsenic trioxide in combination
with local radiotherapy. Int J Hematol 83(4):337–340. doi:10.1532/IJH97.05167
Kao SC, Yuh WT, Sato Y, Barloon TJ (1987) Intracranial granulocytic sarcoma
(chloroma): MR findings. J Comput Assist Tomogr 11(6):938–941
King A (1853) A case of chloroma. Monthly J Med Soc 17:97
Libson E, Bloom RA, Galun E, Polliack A (1986) Granulocytic sarcoma (chloroma)
of bone: the CT appearance. Comput Radiol 10(4):175–178
Licht JD (2009) Acute promyelocytic leukemia–weapons of mass differentiation.
N Engl J Med 360(9):928–930. doi:10.1056/NEJMcibr0810371Milone G, Inghilterra G, Li Gioi F, Peluso D, Giustolisi R (1999) Testicular and
cutaneous relapse after hematopoietic transplantation in a patient affected
with APL. Bone Marrow Transplant 23(7):751. doi:10.1038/sj.bmt.1701625
Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, Holowiecka
A, Esteve J, Bergua J, Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J,
Manso F, Milone G, de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM,
Escoda L, Lowenberg B, Sanz MA (2011) Clinical significance of CD56
expression in patients with acute promyelocytic leukemia treated with all-
trans retinoic acid and anthracycline-based regimens. Blood 117(6):1799–
1805. doi:10.1182/blood-2010-04-277434
Mwanda WO, Rajab JA (1999) Granulocytic sarcoma: report of three cases. East
Afr Med J 76(10):594–596
Naina HV, Levitt D, Vusirikala M, Anderson LD Jr, Scaglioni PP, Kirk A, Collins RH Jr
(2011) Successful treatment of relapsed and refractory extramedullary acute
promyelocytic leukemia with tamibarotene. J Clin Oncol 29(18):e534–e536.
doi:10.1200/JCO.2011.34.8953
Ochs RC, Gormley RH, Luger S, Bagg A (2010) Isolated bowel relapse in acute
promyelocytic leukemia: an unusual site of extramedullary recurrence. J Clin
Oncol 28(29):e550–e553. doi:10.1200/JCO.2010.29.7424
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, Piccaluga PP,
Agostinelli C, Asioli S, Novero D, Bisceglia M, Ponzoni M, Gentile A, Rinaldi P,
Franco V, Vincelli D, Pileri A Jr, Gasbarra R, Falini B, Zinzani PL, Baccarani M
(2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic
analysis of 92 adult patients. Leukemia 21(2):340–350. doi:10.1038/sj.
leu.2404491
Ruiz-Arguelles GJ, Gomez-Almaguer D, Vela-Ojeda J, Morales-Toquero A, Gomez-
Rangel JD, Garcia-Ruiz-Esparza MA, Lopez-Martinez B, Cantu-Rodriguez OG,
Gutierrez-Aguirrec CH (2005) Extramedullary leukemic relapses following
hematopoietic stem cell transplantation with nonmyeloablative conditioning.
Int J Hematol 82(3):262–265. doi:10.1532/IJH97.04195
Sadovnikova E, Parovichnikova EN, Savchenko VG, Zabotina T, Stauss HJ (2002)
The CD68 protein as a potential target for leukaemia-reactive CTL. Leukemia
16(10):2019–2026. doi:10.1038/sj.leu.2402635
Sanz MA, Larrea L, Sanz G, Martin G, Sempere A, Gomis F, Martinez J, Regadera A,
Saavedra S, Jarque I, Jimenez C, Cervera J, de La Rubia J (2000) Cutaneous
promyelocytic sarcoma at sites of vascular access and marrow aspiration. A
characteristic localization of chloromas in acute promyelocytic leukemia?
Haematologica 85(7):758–762
Ustun C, Arat M, Celebi H, Akan H, Ilhan O, Ozcelik T, Burgess RE, Koc H (2001)
Extramedullary relapse following allogeneic stem cell transplantation in acute
promyelocytic leukemia: the role of ATRA. Haematologica 86(10):E31
Weiss MA, Warrell RP Jr (1994) Two cases of extramedullary acute promyelocytic
leukemia. Cytogenetics, molecular biology, and phenotypic and clinical
studies. Cancer 74(7):1882–1886
Wiernik PH, De Bellis R, Muxi P, Dutcher JP (1996) Extramedullary acute
promyelocytic leukemia. Cancer 78(12):2510–2514
doi:10.1186/2193-1801-2-49
Cite this article as: Kothari et al.: Multiple isolated extramedullary
relapse of acute promyelocytic leukemia after allogeneic hematopoietic
stem cell transplant: a case report and review of literature. SpringerPlus
2013 2:49.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
